Pharma and profits : balancing innovation, medicine, and drug prices / John L. LaMattina.
Material type:
TextHoboken, NJ : John Wiley & Sons, 2022Description: xii, 100 pages ; 23 cmLOC classification: - Allied HD 9666.4 L36 2022
| Item type | Current library | Call number | Copy number | Status | Barcode | |
|---|---|---|---|---|---|---|
| Books | EAC Library Cavite EAC Cavite-Allied Health Sciences Section | Allied HD 9666.4 L36 2022 c.2 (Browse shelf(Opens below)) | c2 | Available | ML17504 | |
| Books | EAC Library Cavite EAC Cavite-Allied Health Sciences Section | Allied HD 9666.4 L36 2022 (Browse shelf(Opens below)) | c.1 | Available | ML16622 |
Includes index.
ch. 1. The $1000 pill: the fiscal consequences of curing hepatitis C — ch. 2. Enter the players: FDA approval does not guarantee commercial success — ch. 3. Pandemic: mRNA vaccine and the race for a cure — ch. 4. Federal investment in r&d: why the government does not deserve a piece of biopharma’s profits? — ch. 5. Inaulin: the true cost of a 100-year-old drug — ch. 6. The costly alzheimer’s disease drug: a questionable breakthrough — ch. 7. Gene therapy: how much a life worth? — ch. 8. Proving the value of expensive drug: should we pay for drugs whose ultimate value is unknown? — cn. 9. Generic drugs: built-in cost controls — ch. 10. About those soaring pharma profits: are they driving healthcare costs? — ch. 11. Schemes to lower drug prices: the impact of reduced resources on r&d.
There are no comments on this title.